Biomarkers for Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.
Aim(s): In this study we have assessed these markers in three cohorts of NET patients to determine how they compared with NTP.
Materials and methods: 3 groups of sbNET patients (n=37) were identified: CHD (Group A, n=10), non-functional (Groups B, n=12, normal CgA, 5HIAA, BNP), functional (Group C, n=15, elevated chromogranin A (CgA) & urine 5HIAA, normal BNP). Analysis was performed using NTP, GAL3, ST2, calprotectin and adrenomedullin assays. Statistical analysis was performed with SPSS.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Srirajaskanthan R
Keywords: carcinoid heart disease,
To read the full abstract, please log into your ENETS Member account.